ReviewJournal of the American Society of Nephrology : JASN2015
Considerations and challenges in defining optimal iron utilization in hemodialysis.
Review in Journal of the American Society of Nephrology : JASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Effect of Intravenous Iron Dextran on Kidney Outcomes in Acute Kidney Injury with Iron Deficiency: A Randomized Trial.Kidney360 · 2026Trial
- Maintenance intravenous iron in hemodialysis patients to minimize erythropoietin doses: a double-blinded, randomized controlled trial (the MAINTAIN IRON trial).Scientific reports · 2023Trial
- Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.British journal of clinical pharmacology · 2019Trial
- Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial .Clinical nephrology · 2019Trial
- Trial
- Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis.Pediatric nephrology (Berlin, Germany) · 2018Trial
- The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.BMC nephrology · 2017Trial
- Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study.BMC nephrology · 2017Trial
- Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers.Journal of clinical pharmacology · 2017Trial
- Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.BMC nephrology · 2016Trial
- Trial
- Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.Journal of the American Society of Nephrology : JASN · 2016Trial
- Bidirectional Mendelian Randomization analysis of iron status and uremia: no evidence of a causal relationship.Renal failure · 2025Article
- A deterministic large language model (LLM) framework for safe, protocol-adherent clinical decision support: application in hemodialysis anemia management (AnemiaCare HDs).Frontiers in artificial intelligence · 2025Article
- Association of iron therapy with incidence of chronic kidney disease.European journal of haematology · 2023Article
- Association of oral iron replacement therapy with kidney failure and mortality in CKD patients.Clinical kidney journal · 2023Article
- Article
- Activation of STAT and SMAD Signaling Induces Hepcidin Re-Expression as a Therapeutic Target for β-Thalassemia Patients.Biomedicines · 2022Review
- Coronary artery bypass grafting vs. percutaneous coronary intervention in coronary artery disease patients with advanced chronic kidney disease: A Chinese single-center study.Frontiers in surgery · 2022Article
- Iron Sucrose: A Double-Edged Sword in High Phosphate Media-Induced Vascular Calcification.Calcified tissue international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Trials raising concerns about erythropoiesis-stimulating agents, revisions to their labeling, and changes to practice guidelines and dialysis payment systems have provided strong stimuli to decrease erythropoiesis-stimulating agent use and increase intravenous iron administration in recent years. These factors have been associated with a rise in iron utilization, particularly among hemodialysis patients, and an unprecedented increase in serum ferritin concentrations. The mean serum ferritin concentration among United States dialysis patients in 2013 exceeded 800 ng/ml, with 18% of patients exceeding 1200 ng/ml. Although these changes are broad based, the wisdom of these practices is uncertain. Herein, we examine influences on and trends in intravenous iron utilization and assess the clinical trial, epidemiologic, and experimental evidence relevant to its safety and efficacy in the setting of maintenance dialysis. These data suggest a potential for harm from increasing use of parenteral iron in dialysis-dependent patients. In the absence of well powered, randomized clinical trials, available evidence will remain inadequate for making reliable conclusions about the effect of a ubiquitous therapy on mortality or other outcomes of importance to dialysis patients. Nephrology stakeholders have an urgent obligation to initiate well designed investigations of intravenous iron in order to ensure the safety of the dialysis population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.